A B S T R A C T Studies of the effect of L-thyroxine administration (0.3 mg daily for 7-9 wk) on the peripheral metabolism of "'I-labeled triiodothyronine (Ta) and "IIlabeled thyroxine (T4) and on the concentration and binding of T4 and Ts in serum were carried out in 11 euthyroid female subjects. Administration of L-thyroxine led to consistent increases in serum Ta concentration (137 vs. 197 ng/100 ml), Ta distribution space (39.3 vs. 51.7 liters), Ta clearance rate (22.9 vs. 30.6 liters/ day) and absolute Ts disposal rate (30 vs. 58 Ag/day), but no change in apparent fractional turnover rate (60.3 vs. 60.6%/day). The proportion and absolute concentration of free Ta also increased during L-thyroxine administration. Increases in serum total T4 concentration (7.3 vs. 12.8 ,g/100 ml) and in both the proportion and absolute concentration of free thyroxine also occurred. In five of the subjects, the kinetics of peripheral T4 turnover were simultaneously determined and a consistent increase in fractional turnover rate (9.7 vs. 14.2%/day), clearance rate (0.84 vs. 1.37 liters/day), and absolute disposal rate (64.2 vs. 185.0 Ag/day) occurred during L-thyroxine administration. Despite these increases in the serum concentration and daily disposal rate of both To and Ta, the patients were not clinically thyrotoxic. However, basal metabolic rate (BMR) values were marginally elevated and, as in frank thyrotoxicosis,
INTRODUCTION
In 1970, studies from our laboratories provided the first conclusive evidence that thyroxine (T4)1 is converted 1 Abbreviatiots used in this paper: ETT4, extrathyroidal T4 pool; %FTs, per cent free Ts; %FT4, per cent free T4; SSKI, saturated solution of potassium iodide; TBG, thyroxine-binding globulin; TBGcap, measurements of T4-binding capacities by TBG; TBPA, thyroxine-binding prealbumin; to triiodothyronine (T3) in the peripheral tissues of man (1) . This conclusion has since been repeatedly confirmed (2) (3) (4) (5) , and conversion of T. to Ts has been demonstrated, in addition, in the intact rat (6) and in isolated human cells in vitro (7) (8) (9) . Our conclusion was based in part on the finding that athyreotic patients receiving exogenous L-thyroxine therapy had in their serum concentrations of Ts far greater than those which would have been expected on the basis of contamination of the administered To by Ts (1) . An unexplained feature of this study was the finding that although these patients did not appear thyrotoxic by clinical criteria, serum T4 concentrations were well into the range found in spontaneously thyrotoxic patients, and serum T3 concentrations also appeared distinctly elevated by the methods of analysis then available.
In an effort to examine this apparent discrepancy, to examine the conjointly-measured kinetics of peripheral T4 and Ts metabolism in patients receiving L-thyroxine, and to assign quantitative dimensions to the extent of peripheral conversion of T4 to Ts, studies were conducted in which the effects of L-thyroxine on the peripheral metabolism of To and Ts in euthyroid individuals were assessed. A portion of the studies has been the subject of a preliminary communication (10) .
METHODS
Studies were conducted in 11 normal female volunteers ranging from 22 to 54 yr in age. Studies of the peripheral metabolism of Ts were carried out in all 11 before and after a 7-9 wk period of L-thyroxine administration (0.3 mg/day orally [P.O.]). In five, studies of the peripheral metabolism of To were conducted concurrently with those of Ts.
Studies of the peripheral metabolism of Ts were made using 'I-labeled Ta.2 After its receipt from a commercial source, labeled Ts was mixed with sterile human serum albumin (final concentration 4 g/100 ml) and was dialyzed against 2 liters of sterile physiological saline solution at 4VC for 2 h. As judged by chromatography in two (11) . 
RESULTS
Concentration and binding of TJ in serum (Table I) . (Table III) . Before L-thyroxine administration, indices of the peripheral (2) (3) (4) (5) and has been extended to the rat (6), has raised inter-related questions as to the origin of the Ts found in serum, the nature of the thyroidal secretory product, and the ultimately active form of the thyroid hormone. Central to each of these questions is the actual extent of peripheral conversion of To to Ta; however, such could not be determined from our previous studies in athyreotic patients, since the rates of turnover and clearance of T4 and Ts were not ascertained.
The present studies were undertaken to explore this and other questions concerning thyroid hormone physiology in patients receiving replacement doses of L-thyroxine. Studies were conducted in euthyroid subjects so that absolute rates of T4 and Ts turnover and disposal during L-thyroxine administration could be compared with those obtained in the basal state. Moreover, in view of the marked suppression of thyroid function produced by L-thyroxine administration, as evidenced by decreases in 24 h thyroid 'I uptakes from a mean of 28 to a mean of 3%, T3 present in serum during this period can be considered to have arisen largely or entirely from extrathyroidal sources, permitting estimates of the rate of T4 to Ts conversion.
The normal or increased concentrations of Ts found in serum of the present patients during L-thyroxine administration have confirmed the findings obtained in the anatomically athyreotic patients reported earlier. 5 In addition, in the five patients in whom concurrent studies of T4 and Ts disposal were carried out, the extent to which To was converted to Ts during L-thyroxine administration could be estimated, since thyroidal secretion of Ts could be presumed to be negligible. Calculated values for the per cent of To converted to T3 ranged from 30 The finding that about one-third or one-half of the peripheral T4 is metabolized to T3, together with the twoor threefold greater metabolic potency of Ts than T4, has led to the suggestion that virtually all of the metabolic activity of Ti resides in the Ts generated from it and that T4 is merely a prohormone for Ts. Several considerations prompt caution in this interpretation, however. All estimates of T4 to T3 conversion to date have been what might be termed "plasma conversion rates," since they are based on concentrations and disappearance rates for T3 in plasma. They do not reflect any Ts generated from T4 that is locally degraded or excreted without entering the plasma. The extent to which true conversion rates exceed plasma conversion rates is unknown. Moreover, it is unknown whether Ta generated and metabolized locally has any metabolic action and, if it does, how its intrinsic potency compares with that of T3 that enters the cell from the extracellular fluid. In view of these uncertainties, conclusions concerning the intrinsic potency of T4 based on the fractional conversion of T4 to T3 and the overall potency of the two in the whole animal would seem premature.
Plasma conversion rates do bear directly, however, on the proportion of total daily disposal of T3 that is derived from the monodeiodination of T4, when disposal rates are based upon plasma disappearance rates and plasma concentrations of the two hormones. Thus, the plasma T4 to Ts conversion rate times the daily disposal of T4, when corrected for the lower molecular weight of T3, will indicate the quantity of T3 in plasma derived from T4 daily. The present estimates of conversion rates derived from data obtained while patients were receiving L-thyroxine, when applied to the present conjoint measurements of T4 and T3 disposal in the basal state, would indicate that approximately 60% of daily T3 disposal (and of plasma T3 concentration) derives from the monodeiodination of T4.
At the time these studies were carried out, the effect of labeled iodoproteins arising from Ts deiodination on the apparent disappearance from the serum of the labeled T3 was just becoming evident (22) . Hence, separation of labeled iodoproteins from the labeled T3 remaining in serum was not carried out, although removal of labeled iodide was. The question arises, therefore, as to the extent to which the measured kinetics of T3 metabolism were influenced by failure to exclude iodoprotein. It is most unlikely that this influenced the results of control studies materially, since values for 6 Cullen, M. J., A. Burger, K. A. Woeber, and S. H. Ingbar. Unpublished observations. T3DS and fractional turnover rate did not differ substantially from those obtained when labeled iodoprotein is excluded (19) . This is doubtless the result of the fact that in normal individuals iodoprotein contributes but little to the plasma radioactivity during the 24 to 72 h period in which measurements are made (17) . (17) , iodoprotein is but a small percentage of total organically-bound radioiodine at 24 h after labeled T3 administration and is a progressively larger proportion at later times, then the zero time intercept of the least squares regression curve based on total organic radioiodine would be erroneously low and values for T3DS erroneously high. This spurious increase in T3DS would tend to reduce, but not eliminate, the error in calculated values for T3 clearance caused by underestimation of the fractional turnover rate. The magnitude of such an error is difficult to estimate, however, since there have apparently been no studies in which sera freed of radioiodide were studied with and without removal of iodoprotein to ascertain the magnitude of the effect of including iodoprotein on calculated values of T3DS and fractional turnover rate.7 It is apparent, however, that, to the extent that T3 clearance was underestimated, then the percentage peripheral conversion of T4 to Ts would have been proportionately underestimated and calculated values for the thyroidal secretion of Ts too high. The close agreement between values for T4 to T3 conversion found in the present studies and those found in the studies of Pittman, Surks, and Cullen and their respective co7Nicoloff, Low, Dussault, and Fisher (19) have published curves depicting plasnia disappearance of total radioactivity and iodothyronine radioactivity after administration of labeled Ts. From these curves it is quite clear that values for both T3DS and k would be greatly reduced if total plasma radioactivity, rather than iodothyronine activity, were considered. However, since inorganic iodide comprises approximately 40% of total plasma radioactivity after a dose of labeled T3 (17) , much of the apparent decrease in T3DS can be ascribed to inclusion of iodide, rather than iodoprotein.
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.101.5 workers (2, 4) in which iodoprotein was eliminated from serum before analysis, would suggest, however, that the error introduced by our failure to eliminate iodoproteins was satll.
Until recently, it has been assumed that adequate replacement therapy with L-thyroxine would require doses sufficient to establish values for serum T4 concentration above the normal range, since the metabolic contribution normally provided by Ts was presumed to be lacking (23) (24) (25) (26) (27) . With the demonstration of peripheral T4 to Ts conversion, however, the rationale for this approach no longer seemed valid, provided that the rate of production of Ta was physiologically significant. Although our earlier studies of athyreotic patients receiving L-thyroxine therapy revealed normal or increased concentrations of serum Ts, production rates could not be inferred, since peripheral Ts turnover was not studied under these circumstances.
The present studies have shown, however, that euthyroid patients receiving 0.3 mg L-thyroxine daily undergo at least a doubling in the daily disposal rate for Ts and a trebling in that for T4, as compared to the production and disposal rates sustained by their endogenous thyroid function. It would appear, therefore, that the conventional replacement dose of 0.3 mg of L-thyroxine daily does provide both T4 and Ts in excess of normal physiological requirements. One might then expect patients receiving this dose to manifest signs of thyroid hormone excess. Frank thyrotoxicosis would be unlikely in view of the fact that quantities of T4 and T3 provided by 0.3 mg L-thyroxine daily, although greater than normal, were far less than the usual production rates of T4 and T3 in hyperthyroid patients, as judged from reports in the literature (17, 19, (28) (29) (30) (31) (32) (33) . The present patients manifested no clinical signs of thyrotoxicosis. On the other hand, several findings provide suggestive though not conclusive evidence that they were mildly hypermetabolic. First, in six of the eight patients, values of the BMR (+ 8-+ 15%) during suppressive therapy were above the normal range for our laboratory (-15-+ 5%); however, in none were pretreatment values available.
Second, TBGcap and TBPAcp decreased during L-thyroxine therapy, changes reminiscent of those found in patients with spontaneous thyrotoxicosis (34, 35) . The few available data of other workers also supports the conclusion that 0.3 mg of L-thyroxine daily may often be an excessive replacement dose. Most authors emphasize the difficulty of selecting between 0.2 mg daily and 0.3 mg daily on the basis of subjective findings alone (26, 27, (36) (37) (38) ; however, when objective criteria such as BMR have been assessed, doses of 0.2 mg daily frequently seem sufficient (36, 39) . The most telling evidence, however, is the recent finding of Cotton, Gorham, and Mayberry (40) that in patients with hypothyroidism doses of 0.2 mg daily usually suffice to restore serum thyroid-stimulating hormone (TSH) concentration to normal.
The apparent physiological (and clinical) tolerance of euthyroid young adults to slight or moderate excesses of thyroid hormone is well-known, particularly from instances where the hormone is administered in an effort to treat obesity. In addition, patients with autonomous thyroid nodules and complete suppression of paranodular thyroid function often are not detectably thyrotoxic, although it is most unlikely that the nodule is secreting quantities of hormone precisely equivalent to physiological needs. Such apparent resistance to mild excesses of thyroid hormone may merely bespeak the insensitivity of clinical and biochemical indices of thyroid hormone excess currently available. It might also reflect enhanced activity of pathways for hormonal metabolism that are purely degradative or excretory, i.e., that forestall hormonal action. Finally, to the extent that hormonal excess is judged to exist on the basis of increased serum concentration or disposal rate of T4, the validity of such judgments will depend upon the extent to which T4 proves to have a metabolic action independent of its conversion Ts. All of these considerations, and perhaps others, await clarification.
